Voya Investment Management LLC raised its holdings in shares of Aduro Biotech, Inc. (NASDAQ:ADRO) by 15.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,935 shares of the biotechnology company’s stock after purchasing an additional 2,515 shares during the period. Voya Investment Management LLC’s holdings in Aduro Biotech were worth $216,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in shares of Aduro Biotech by 283.7% during the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after purchasing an additional 275,295 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Aduro Biotech by 5.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock valued at $1,560,000 after purchasing an additional 7,812 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Aduro Biotech by 2.1% during the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock valued at $25,617,000 after purchasing an additional 48,840 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Aduro Biotech by 3.8% during the first quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock valued at $1,593,000 after purchasing an additional 5,470 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new position in shares of Aduro Biotech during the second quarter valued at approximately $408,000. 43.10% of the stock is owned by institutional investors and hedge funds.

ADRO has been the subject of a number of analyst reports. BidaskClub raised shares of Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. HC Wainwright set a $18.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Aduro Biotech in a research note on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $19.14.

In related news, CEO Stephen T. Isaacs sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $10.78, for a total value of $431,200.00. Following the sale, the chief executive officer now owns 213,921 shares in the company, valued at $2,306,068.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jennifer Lew sold 6,600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $8.95, for a total transaction of $59,070.00. Following the completion of the sale, the insider now owns 68,938 shares in the company, valued at approximately $616,995.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 224,480 shares of company stock worth $2,194,001. Corporate insiders own 6.60% of the company’s stock.

Shares of Aduro Biotech, Inc. (NASDAQ ADRO) opened at $8.80 on Monday. Aduro Biotech, Inc. has a fifty-two week low of $6.01 and a fifty-two week high of $14.85.

Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. During the same quarter in the previous year, the company earned ($0.54) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts forecast that Aduro Biotech, Inc. will post -1.28 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2017/11/20/voya-investment-management-llc-has-216000-holdings-in-aduro-biotech-inc-adro.html.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.